全部树

China university patent statisticsNEW

China high-tech enterprise patent statisticsNEW

Digital economy patent application and authorization dataNEW

Patents and citation data of Little Giant and individual champion companiesNEW

Small giant and single champion enterprise design patent details table

Statistics on the entry and exit of Chinese industrial and commercial enterprisesNEW

Statistics on entry and exit information of Chinese partnershipsNEW

Basic information data of manufacturing industrial and commercial registered enterprisesNEW

Patent and citation data of A-share listed companiesNEW

Patent details of A-share listed companies
A-share listed companies' patent application details table
Details of Design Patents Authorized by A-share Listed Companies

Green patents and citation data of A-share listed companies

A-share listed companies green patent details table

Patent and citation data of Chinese industrial enterprisesNEW

Green patents and citation data of Chinese industrial enterprisesNEW

Details of Green Patents of Chinese Industrial Enterprises

Tax investigation of corporate patents and citation dataNEW

Cost of living data for global residentsNEW

China foreign trade index data

  The 2019 novel coronavirus (2019-nCoV), discovered through cases of viral pneumonia in Wuhan in 2019, was officially named by the World Health Organization on January 12, 2020. Coronaviruses constitute a large family of viruses known to cause illnesses ranging from common colds to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The novel coronavirus represents a new strain previously unidentified in humans.

  On January 21, 2020, the National Health Commission issued Announcement No. 1, classifying pneumonia caused by the novel coronavirus as a Category B infectious disease under the Law of the People's Republic of China on the Prevention and Treatment of Infectious Diseases, while implementing preventive and control measures for Category A infectious diseases. Over eighteen months since its initial large-scale outbreak, the Chinese government has accumulated substantial experience in epidemic containment. However, the pandemic persists, with continuous efforts across China and globally to combat the virus. During the early stages, China rapidly isolated the virus, completed whole-genome sequencing, developed nucleic acid detection kits, and received WHO recognition for its sequencing speed. Although no specific treatment exists for COVID-19, many symptoms can be managed through clinical care, while vaccine and therapeutic development remains urgently prioritized.

  The CnOpenData platform aggregates patent information related to COVID-19 prevention, providing foundational support for scientific research and clinical treatment. The dataset encompasses multiple domains: therapeutic drugs, prophylactic medications, detection and diagnostic kits, medical devices, protective equipment, medical disinfection, medical waste treatment, and wastewater management, aiming to facilitate coronavirus analysis, scientific epidemic control, and drug development.

  The CnOpenData team supports medical research and public health initiatives by opening access to COVID-19 prevention patent information data (contact customer service for access), with the hope of accelerating pandemic containment efforts.


Temporal Coverage

By filing date:

  • Chinese Epidemic Prevention Patent Information: July 1992 - December 2019
  • Global Epidemic Prevention Patent Information: April 1912 - August 2019

By publication date:

  • Chinese Epidemic Prevention Patent Information: April 1993 - January 2020
  • Global Epidemic Prevention Patent Information: June 1913 - October 2019

Data Structure Visualization

COVID-19 Prevention Patent Data Structure Diagram


Field Specifications


Sample Data

Chinese Epidemic Prevention Patent Information

Chinese Patent Legal Status Information

Global Epidemic Prevention Patent Information


Data Update Frequency

Annual updates